Physician profile
Eildar Abyar
NPI 1750769170
$31,549.36
in general payments reported to CMS, 2019-2025
16 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22K · 2021: $3,872 · 2022: $770 · 2023: $853 · 2024: $2,929 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812 · Travel and Lodging: $1,466 · Education: $89.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.90 |
| Travel and Lodging | $1,465.74 |
| Education | $89.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $20,251.00 | 2020-2021 | |
| Stryker Corporation | $3,147.40 | 2020-2025 | Blueprint Patient Specific Instrumentation, Mako, Pangea |
| Depuy Synthes Sales INC. | $2,179.76 | 2020-2025 | Motoband, Va-Lcp, Na |
| Medinc of Texas | $1,826.66 | 2020-2024 | |
| Medical Device Business Services, INC. | $1,340.54 | 2021-2025 | Motoband |
| Djo, LLC | $1,250.00 | 2020 | |
| Abbvie INC. | $557.57 | 2023-2025 | Botox |
| Smith+Nephew, INC. | $298.59 | 2021-2022 | |
| Galderma Laboratories, L.P. | $158.33 | 2023-2024 | |
| Zimmer Biomet Holdings, INC. | $132.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $119.49 | 2025 | Euflexxa |
| Revance Therapeutics, INC. | $97.49 | 2025 | Daxxify |
| Prosidyan, INC | $83.82 | 2021 | |
| Mission Medical Distribution, LLC | $77.96 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.30 | 2025 | Exparel |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $13.45 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eildar Abyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.